Drug and Therapeutics Bulletin 1997;35:57-58; doi:10.1136/dtb.1997.35857
Copyright © 1997 by the BMJ Publishing Group Ltd.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

{blacktriangledown}Humalog - a new insulin analogue

Relevant BNF section: 6.1.1.1

Insulin lispro (Humalog - Lilly) is a genetically engineered human insulin analogue which the manufacturer claims to allow patients "the convenience of injecting immediately before they eat". It is licensed for the treatment of patients who require insulin therapy for maintenance of normal glucose homeostasis and for the initial stabilisation of diabetes mellitus. Here we review insulin lispro and assess its place in the treatment of patients with diabetes.






About DTB - Privacy policy - Terms and conditions relating to subscriptions purchased online - Web site terms and conditions - Feedback

© 1997 BMJ Publishing Group Ltd.